Personalizing arthritis treatment: genes may predict drug success

NCT ID NCT07388407

Recruiting now Knowledge-focused Sponsor: Foundation University Islamabad Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how genetic differences influence the effectiveness and side effects of leflunomide, a common rheumatoid arthritis drug. Researchers will recruit 110 Pakistani patients starting leflunomide and track their disease activity and side effects over six months. By analyzing DNA from blood samples, they hope to find genetic markers that predict who responds well and who experiences toxicity, potentially leading to more personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leflunomide
What this could lead to: If successful, this could help doctors predict which rheumatoid arthritis patients will benefit most from leflunomide and who might have side effects.
What could go wrong: This is an early observational study with only 110 participants. Results may not apply to all populations, and the genetic markers found may not reliably predict outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEMATOID ARTHRITIS

Contacts and locations

Locations

Fauji Foundation Hospital, Rawalpindi
RECRUITING

Rawalpindi, Punjab Province, 46000, Pakistan
Shifa International Hospital
COMPLETED

Islamabad, Punjab Province, 44000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.